March 2025
Published: 28 Feb 2025
Author: Precedence Research
Zydus Lifesciences has launched VaxiFlu-4, a new quadrivalent vaccine against the most recent strains of influenza that have mutated in India. The development of this product was undertaken by the Vaccine Technology Centre in Ahmedabad, with the intent of providing broad protection against the flu under a general WHO suitability for the 2025 southern hemisphere influenza season.
Zydus Vaxxicare offers Vaxflu-4 as a quadrivalent inactivated influenza vaccine. It is prepared for the vaccine’s use to help control the occurrence of any one of the four mentioned affecting strains which are; swine influenza virus, A/Victoria/4897/2022 (H1N1)pdm09-like virus, A/Croatia/10136RV/2023 (H3N3) -like a virus, B/Austria/1359417/2021 (B/Victoria lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. This vaccine which can provide protection and often prevents the occurrence of flu is ready for distribution throughout the country.
Influenza, which infects 290,000 to 650,000 people every year, is a major public threat in India. Zydus Lifesciences, the leading preventive health provider, develops cheap and technologically advanced quality vaccines against influenza outbreaks. VaxiFlu-4's launch is evidence that the company keeps its promises related to immunization to better public health in developing and developed societies. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, believes in improving the quality of life, enhancing public health, and giving life-long supplement immunity through annual vaccination against the flu, which is common in most countries.
The Vaccine Technology Centre (VTC) of Ahmedabad is associated with the development and manufacture of the Vaccine VaxiFlu-4, which follows a global regulatory standard. Thus, Zydus Lifesciences has displayed innovation in the vaccine by bringing forth the launch of VaxiFlu-4. Influenza control remains a major public health concern. This is because it is a virus characterized by mutations. Hence, the regulators push for up-to-date vaccines each influenza season. Preventive healthcare initiatives and government-run vaccination programs will further enhance awareness and adoption of flu vaccines in India, such as VaxiFlu-4. Strengthening public health policies and increasing vaccination coverage together are effective deterrents against illness from influenza.
The oldest vaccine designed to combat human influenza strains is still a trivalent vaccine. It protects against three strains of the virus. A much wider range of protection provided by quadrivalent vaccines such as VaxiFlu-4 covers four strains. Expected demand for quadrivalent vaccines will increase with the appearance of new types of influenza. They should be encouraged by the healthcare provider since it can protect against A as well as B viruses. Another way to guard oneself against viruses is through frequent handwashing, wearing masks, cough etiquette, eating proper nutrition, plenty of sleep, and medical aid. These would offer the highest protection against the virus if combined with vaccines.
Zydus Lifesciences has launched VaxiFlu-4, a pan-seasonal vaccine against influenza, which is a big leap for the nation against the flu virus. The company is dedicated to public health and access to vaccines for the fight against flu-related morbidity and complications through quadrivalent influenza vaccination ensuring coverage for all age groups during the upcoming flu season. As of now, the flu season is approaching in 2025.
March 2025
March 2025
March 2025
March 2025